The leading digital therapeutic company focusing on the elderly
Dthera™ Sciences (OTCQB:DTHR) is a San Diego-based publicly traded company working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. It has two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation and dementia; and DTHR-ALZ, a development-stage product that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer’s disease.
Meet the team
Edward Cox has been the Chief Executive Officer and Chairman of the Board of Dthera Sciences since September 2016. Previously, he was Chairman and Chief Executive Officer of EveryStory, which merged with Dthera Sciences. Prior to EveryStory, he was an Executive Officer at Apricus Biosciences, a NASDAQ listed pharmaceutical company. In the 5 years he was at Apricus, he led Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox served as the President and Director of Bio-Quant, Inc. from January 2007 until Bio-Quant’s merger with NexMed, Inc., which was renamed Apricus Biosciences. Prior to late 2009, Mr. Cox served as an executive or board member of both public and private companies in the areas of Healthcare, Life Science, Technology and Resources. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.
David Keene was appointed as Dthera’s Chief Technology Officer and a member of Dthera’s Board of Directors in connection with the EveryStory Transaction. Mr. Keene, the founder of EveryStory and a member of EveryStory’s Board of Directors, is a veteran of the video game industry who has specialized in commerce and content delivery. Prior to founding EveryStory, from 2010 to 2013, Mr. Keene served as Chief Architect – Commerce Platform for Trion Worlds, Inc. At Trion, Mr. Keene led a group of senior engineers to create an innovative, world class commerce platform. Prior to Trion, Mr. Keene served as Senior Architect for the Sony PlayStation Network. While at Sony, Mr. Keene managed integrations with multiple global partner groups, added search and recommendation systems and oversaw the development of Sony’s content delivery and online commerce worldwide. He has advised and contributed to the commerce systems for many popular video game franchises.
Board of Directors
Larry Morgan was appointed to Dthera’s Board of Directors in connection with the closing of the EveryStory Transaction. Mr. Morgan recently joined the EveryStory board of directors, and is a top-flight executive with over 25 years of global experience in the telecom, IT services, enterprise restructuring, and consulting industries. Mr. Morgan is currently President and CEO of The Noble Group, a consulting firm that advises early stage companies on growth strategies and advises the managements of seasoned companies regarding exit strategies. Mr. Morgan is also an active investor with Vertical Venture Partners, Tech Coast Angels and OurCrowd. From 2010 to 2013, Mr. Morgan served as Executive Director of San Diego Data Processing Corporation and led a restructuring that resulted in annual savings in excess of $11 million to the City of San Diego. Prior to that, from 2007 to 2009, Mr. Morgan served as a Managing Director of Macquarie Telecom, where he led the turnaround of the international hosting, voice and data outsourcing division and led the sale of the resulting profitable business. In addition to domestic postings, during his tenure with Macquarie, Mr. Morgan had postings in Australia and Singapore, Prior to Macquarie, from 2005 to 2006, Mr. Morgan served as President and CEO of Virtela Communications, spearheading the turnaround that resulted in the foundation for Virtela’s eventual sale for over $500 million. Prior to Virtela, from 1991 to 2005, Mr. Morgan had several executive positions of increasing responsibility with Infonet Services Corporation, and last served as Corporate Vice President and General Manager. During his tenure with Infonet, Mr. Morgan led Infonet’s business in Europe, the Middle East and Africa, was responsible for all IP, outsourcing and cloud computing products, expansion into India, network coverage in 61 countries, and was a member of the executive due diligence and transition team in connection with the company’s sale to British Telecom for $965 million. Also during his tenure with Infonet, Mr. Morgan had international postings in The Netherlands and Singapore. Mr. Morgan holds both a B.S. degree (Mathematics and Education) and an M.A. degree (Administration) from Villanova University.
Board of Directors
Steve Martin was appointed to Dthera’s Board of Directors in April 2018. Mr. Martin has over 30 years of progressive experience in senior financial roles including leadership positions in publicly-traded companies in the life sciences, software and telecommunications industries. Mr. Martin is currently Senior Vice President and Chief Financial Officer of AmpliPhi Biosciences, a publicly-traded anti-infectious disease development company. Mr. Martin’s previous experiences include serving as CFO of Apricus Biosciences and Stratagene, both publicly traded life sciences companies with commercial products, and as CFO and interim CEO of BakBone Software, which was sold to Quest Software under his leadership. Mr. Martin was also Chief Accounting Officer of Leap Wireless, also known as Cricket Communications, then an independent $2 billion cell phone and data communications company. Mr. Martin is the past President of Financial Executives International, San Diego and served on its Board of Directors. He began his career at Deloitte where he rose to the position of Senior Audit Manager. Mr. Martin has a Bachelor of Science from San Diego State University.
Amir Kalali, M.D.
Board of Directors
Amir Kalali was appointed to Dthera’s Board of Directors in October 2018. Dr. Kalali is recognized globally as a leading innovator at the intersection of life sciences and technology, advising companies on building the future of their business at the board level or as a strategic advisor. Previously, he was the Global Head of the Neuroscience Center of Excellence at Quintiles, now known as IQVIA. In this role, he led the enterprise-wide strategy for neuroscience, and was responsible for numerous successful clinical development programs that led to many new treatments for patients. He is Clinical Professor of Psychiatry at the University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development. He was Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), a founding member of the International Society for CNS Clinical Trials and Methodology (ISCTM), where he serves on the Executive Committee, and Founder and Chief Curator of the CNS Summit. Dr. Kalali has been the recipient of many awards, including the ISCDD Leadership in CNS Drug Development Award. In 2005, 2006, 2008, 2011 and 2012 PharmaVOICE magazine named Dr. Kalali as one its 100 most inspiring leaders in the life sciences as voted by his peers. In 2014 he was honored with the PharmaVOICE Inaugural Red Jacket award, recognizing those who have been most lauded by their peers since the awards began.